These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 1439632)

  • 1. Long-term evaluation of penicillamine or cyclofenil in systemic sclerosis. Results from a two-year randomized study.
    Akesson A; Blom-Bülow B; Scheja A; Wollmer P; Valind S; Wollheim FA
    Scand J Rheumatol; 1992; 21(5):238-44. PubMed ID: 1439632
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A 15-year prospective study of treatment of rapidly progressive systemic sclerosis with D-penicillamine [see comment].
    Jimenez SA; Sigal SH
    J Rheumatol; 1991 Oct; 18(10):1496-503. PubMed ID: 1765974
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cyclofenil versus placebo in progressive systemic sclerosis. A one-year double-blind crossover study of 27 patients.
    Blom-Bülow B; Oberg K; Wollheim FA; Persson B; Jonson B; Malmberg P; Boström H; Herbai G
    Acta Med Scand; 1981; 210(5):419-28. PubMed ID: 7039242
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cyclofenil in the treatment of scleroderma - a general view on the results after treating 29 cases.
    Bülow BB; Boström H; Herbai G; Persson B; Wollheim F; Oberg K
    Z Rheumatol; 1980; 39(1-2):1-8. PubMed ID: 7424193
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Scleroderma (progressive systemic sclerosis, PSS); pathophysiological, clinical and pharmacological aspects of the syndrome.
    Herbai G
    Acta Med Acad Sci Hung; 1978; 35(3-4):201-11. PubMed ID: 756110
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improvement of lung function in a scleroderma patient treated for 12 months with cyclofenil.
    Blom-Bülow B; Fridriksson H; Herbai G
    Ups J Med Sci; 1980; 85(1):67-73. PubMed ID: 7385461
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Penicillamine in systemic sclerosis: a reappraisal.
    Sattar MA; Guindi RT; Sugathan TN
    Clin Rheumatol; 1990 Dec; 9(4):517-22. PubMed ID: 2088649
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of D-penicillamine on pulmonary findings in systemic sclerosis.
    Steen VD; Owens GR; Redmond C; Rodnan GP; Medsger TA
    Arthritis Rheum; 1985 Aug; 28(8):882-8. PubMed ID: 4026885
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of progressive systemic sclerosis with a synthetic weak estrogen: cyclofenil (Sexovid). Report of a case.
    Herbai G
    Acta Med Scand; 1974 Dec; 196(6):537-40. PubMed ID: 4456988
    [No Abstract]   [Full Text] [Related]  

  • 10. Treatment of progressive systemic sclerosis (scleroderma, PSS) with a new drug influencing connective tissue.
    Herbai G; Blom B; Boström H
    Acta Med Scand; 1977; 201(3):203-6. PubMed ID: 848357
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cyclofenil treatment of scleroderma--a controlled study.
    Gibson T; Grahame R
    Br J Rheumatol; 1983 Nov; 22(4):218-23. PubMed ID: 6360282
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nodular scleroderma in systemic sclerosis under D-penicillamine therapy.
    Sasaki T; Denpo K; Ono H; Nakajima H
    J Dermatol; 1992 Dec; 19(12):968-71. PubMed ID: 1293190
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of progressive systemic sclerosis (PSS) with cyclofenil.
    Corrocher R; Morittu L; Bambara LM; De Sandre G
    Clin Exp Rheumatol; 1983; 1(4):359-60. PubMed ID: 6681154
    [No Abstract]   [Full Text] [Related]  

  • 14. Treatment of systemic sclerosis with D-penicillamine. A new method of observing the effects of treatment.
    Bluestone R; Grahame R; Holloway V; Holt PJ
    Ann Rheum Dis; 1970 Mar; 29(2):153-8. PubMed ID: 5427411
    [No Abstract]   [Full Text] [Related]  

  • 15. Hepatic reactions to cyclofenil.
    Olsson R; Tyllström J; Zettergren L
    Gut; 1983 Mar; 24(3):260-3. PubMed ID: 6826112
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The progress of oesophageal involvement in progressive systemic sclerosis during D-penicillamine treatment.
    Hendel L; Stentoft P; Aggestrup S
    Scand J Rheumatol; 1989; 18(3):149-55. PubMed ID: 2772562
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum levels of aminoterminal type III procollagen peptide and hyaluronan predict mortality in systemic sclerosis.
    Scheja A; Akesson A; Hørslev-Petersen K
    Scand J Rheumatol; 1992; 21(1):5-9. PubMed ID: 1570489
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictors and outcomes of scleroderma renal crisis: the high-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis trial.
    DeMarco PJ; Weisman MH; Seibold JR; Furst DE; Wong WK; Hurwitz EL; Mayes M; White B; Wigley F; Barr W; Moreland L; Medsger TA; Steen V; Martin RW; Collier D; Weinstein A; Lally E; Varga J; Weiner SR; Andrews B; Abeles M; Clements PJ
    Arthritis Rheum; 2002 Nov; 46(11):2983-9. PubMed ID: 12428241
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Progressive systemic sclerosis and penicillamine.
    Rodnan GP
    J Rheumatol Suppl; 1981; 7():116-20. PubMed ID: 6939873
    [TBL] [Abstract][Full Text] [Related]  

  • 20. D-Penicillamine therapy in progressive systemic sclerosis (scleroderma): a retrospective analysis.
    Steen VD; Medsger TA; Rodnan GP
    Ann Intern Med; 1982 Nov; 97(5):652-9. PubMed ID: 7137731
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.